Treatment of methotrexate-refractory primary central nervous system lymphoma (PCNSL) at Memorial Sloan Kettering Cancer Center

Leuk Lymphoma. 2024 Aug;65(8):1194-1197. doi: 10.1080/10428194.2024.2343778. Epub 2024 May 14.

Authors

Seena Cherian¹, Lisa Modelevsky¹, Anne S Reiner², Christian Grommes³

Affiliations

¹ Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
² Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
³ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

PMID: 38745443
DOI: 10.1080/10428194.2024.2343778

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Central Nervous System Neoplasms* / drug therapy
Drug Resistance, Neoplasm*
Female
Humans
Lymphoma / diagnosis
Lymphoma / drug therapy
Lymphoma / pathology
Male
Methotrexate* / therapeutic use
Middle Aged
Treatment Outcome

Substances

Methotrexate